$216,49
-$4,74(-2,14 %)
*Data last updated: 2026-06-19 02:02 (UTC+8)
As of 2026-06-19 02:02, AbbVie (ABBV) is priced at $216,49, with a total market cap of $382,74B, a P/E ratio of 96,26, and a dividend yield of 3,11 %. Today, the stock price fluctuated between $215,37 and $222,38. The current price is 0,52 % above the day's low and 2,64 % below the day's high, with a trading volume of 5,07M. Over the past 52 weeks, ABBV has traded between $184,38 to $244,81, and the current price is -11,56 % away from the 52-week high.
ABBV Key Stats
Yesterday's Close$221,23
Market Cap$382,74B
Volumen5,07M
P/E Ratio96,26
Dividend Yield (TTM)3,11 %
Dividend Amount$1,73
Diluted EPS (TTM)2,05
Net Income (FY)$4,22B
Revenue (FY)$61,16B
Earnings Date2026-07-30
EPS Estimate3,78
Revenue Estimate$16,77B
Shares Outstanding1,73B
Beta (1Y)0.309
Ex-Dividend Date2026-04-15
Dividend Payment Date2026-05-15
About ABBV
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
SectorHealthcare
IndustryDrug Manufacturers - General
CEORobert A. Michael
HeadquartersNorth Chicago,IL,US
Official Websitehttps://www.abbvie.com
Employees (FY)57,00K
Average Revenue (1Y)$1,07M
Net Income per Employee$74,14K
AbbVie (ABBV) FAQ
What's the stock price of AbbVie (ABBV) today?
x
AbbVie (ABBV) is currently trading at $216,49, with a 24h change of -2,14 %. The 52-week trading range is $184,38–$244,81.
What are the 52-week high and low prices for AbbVie (ABBV)?
x
What is the price-to-earnings (P/E) ratio of AbbVie (ABBV)? What does it indicate?
x
What is the market cap of AbbVie (ABBV)?
x
What is the most recent quarterly earnings per share (EPS) for AbbVie (ABBV)?
x
Should you buy or sell AbbVie (ABBV) now?
x
What factors can affect the stock price of AbbVie (ABBV)?
x
How to buy AbbVie (ABBV) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.